These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 36156312)

  • 1. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).
    Narcisi A; Valenti M; Gargiulo L; Ibba L; Amoruso F; Argenziano G; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Franchi C; Girolomoni G; Guarneri C; Loconsole F; Sampogna F; Travaglini M; Malagoli P; Costanzo A
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):93-103. PubMed ID: 36156312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
    Gargiulo L; Ibba L; Malagoli P; Angileri RG; Bardazzi F; Bernardini N; Burlando M; Carrera CG; Chiricozzi A; Dapavo P; Dini V; Fabbrocini G; Gaiani FM; Galluzzo M; Giofré C; Guarneri C; Loconsole F; Malara G; Marcelli L; Megna M; Piaserico S; Talamonti M; Costanzo A; Narcisi A
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):1017-1027. PubMed ID: 36695061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study.
    Gargiulo L; Ibba L; Pavia G; Vignoli CA; Piscazzi F; Valenti M; Sanna F; Perugini C; Avagliano J; Costanzo A; Narcisi A
    Dermatol Ther (Heidelb); 2022 Oct; 12(10):2309-2324. PubMed ID: 36063283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study.
    Borroni RG; Malagoli P; Gargiulo L; Valenti M; Pavia G; Facheris P; Morenghi E; Di Corteranzo IG; Narcisi A; Ortoncelli M; Dapavo P; Costanzo A
    Acta Derm Venereol; 2021 Nov; 101(11):adv00605. PubMed ID: 34596230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
    Caldarola G; Galluzzo M; Bernardini N; Calabrese L; Grimaldi M; Moretta G; Pagnanelli G; Shumak RG; Talamonti M; Tofani L; Pallotta S; Peris K; Potenza C; De Simone C; Campione E
    Dermatol Ther; 2022 Jun; 35(6):e15488. PubMed ID: 35384168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
    Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
    Berenguer-Ruiz S; Aparicio-Domínguez M; Herranz-Pinto P; Ruíz-Villaverde R; López-Ferrer A; Santos-Juanes J; Rodríguez Fernández-Freire L; Hospital-Gil M; Arias-Santiago S; Carretero-Hernández G; Mateu-Puchades A; Ferran M; Del Alcázar E; Santos-Alarcón S; Garcia-Latasa de Aranibar FJ; Belinchón-Romero I; González-Cantero Á; Ruíz-Genao D; Eiris-Salvado N; Rocamora-Durán V; Rivera-Diaz R; de la Cueva P; Daudén E; Salgado-Boquete L; Llamas-Velasco M;
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):2517-2525. PubMed ID: 37625815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis.
    Di Brizzi EV; Buononato D; Benvenuto P; Argenziano G; De Pasquale R; Fiorella CS; Giofrè C; Musumeci ML; Palazzo G; Zichichi L; Balato A
    Dermatol Pract Concept; 2023 Oct; 13(4):. PubMed ID: 37992389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting.
    Burlando M; Castelli R; Cozzani E; Parodi A
    Drugs Context; 2021; 10():. PubMed ID: 34104197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
    Reich K; Warren RB; Iversen L; Puig L; Pau-Charles I; Igarashi A; Ohtsuki M; Falqués M; Harmut M; Rozzo S; Lebwohl MG; Cantrell W; Blauvelt A; Thaçi D
    Br J Dermatol; 2020 Mar; 182(3):605-617. PubMed ID: 31218661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).
    Gargiulo L; Ibba L; Cascio Ingurgio R; Malagoli P; Amoruso F; Balato A; Bardazzi F; Brianti P; Brunasso G; Burlando M; Cagni AE; Caproni M; Carrera CG; Carugno A; Caudullo F; Cuccia A; Dapavo P; Di Brizzi EV; Dini V; Gaiani FM; Gisondi P; Guarneri C; Lasagni C; Licata G; Loconsole F; Marzano AV; Megna M; Mercuri SR; Musumeci ML; Orsini D; Ribero S; Ruffo Di Calabria V; Satolli F; Strippoli D; Travaglini M; Trovato E; Venturini M; Zichichi L; Valenti M; Costanzo A; Narcisi A
    J Dermatolog Treat; 2024 Dec; 35(1):2350760. PubMed ID: 38714323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
    Imafuku S; Nakagawa H; Igarashi A; Morita A; Okubo Y; Sano S; Tada Y; Nemoto O; Rozzo SJ; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):844-852. PubMed ID: 33523513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.
    Blauvelt A; Sofen H; Papp K; Gooderham M; Tyring S; Zhao Y; Lowry S; Mendelsohn A; Parno J; Reich K
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2305-2312. PubMed ID: 31407394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis.
    Heim J; Vasquez JG; Bhutani T; Koo J; Mathew J; Gogineni R; Ferro T; Bhatia N
    J Drugs Dermatol; 2024 Aug; 23(8):612-618. PubMed ID: 39093661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis).
    Gargiulo L; Ibba L; Malagoli P; Amoruso F; Argenziano G; Balato A; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Fabbrocini G; Franchi C; Gaiani FM; Girolomoni G; Guarneri C; Lasagni C; Loconsole F; Marzano AV; Megna M; Sampogna F; Travaglini M; Costanzo A; Narcisi A
    Front Med (Lausanne); 2023; 10():1196966. PubMed ID: 37469659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
    Elewski B; Menter A; Crowley J; Tyring S; Zhao Y; Lowry S; Rozzo S; Mendelsohn AM; Parno J; Gordon K
    J Dermatolog Treat; 2020 Dec; 31(8):763-768. PubMed ID: 31268369
    [No Abstract]   [Full Text] [Related]  

  • 19. Psoriasis patients' characteristics associated with high PASI response to tildrakizumab: an international dual center study.
    Burlando M; Maul JT; Salvi I; Simic D; Cozzani E; Ak M; Birkenmaier I; Parodi A
    Eur Rev Med Pharmacol Sci; 2022 Sep; 26(18):6772-6776. PubMed ID: 36196725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.